Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

thehindubusinessline.com - Anupama Ghosh - Profit-booking drags Nifty below 25,200; Pharma holds firm as metals, durables bleed
Profit-booking drags Nifty below 25,200; Pharma holds firm as metals, durables bleed
The HinduBusinessLine –

Updated - November 18, 2026 at 01:27 PM. Benchmark indices fell sharply in mid-session trade on Wednesday, with broad-based profit-booking accelerating after the morning open. The Sensex was down 624.97 points or 0.76 per cent at 81,907.22 as of…

marketbeat.com - Nuvectis Pharma, Inc. (NASDAQ:NVCT) Stock Has Consensus Target Price of $36.25
Nuvectis Pharma, Inc. (NASDAQ:NVCT) Stock Has Consensus Target Price of $36.25
MarketBeat –

Nuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) has received an average rating of 'Moderate Buy' from the six brokerages that are covering the company, MarketBeat reports. Two analysts have rated the stock with a sell rating, three have…

marketbeat.com - BridgeBio Pharma, Inc. $BBIO Shares Newly Bought by Aberdeen Group plc
BridgeBio Pharma, Inc. $BBIO Shares Newly Bought by Aberdeen Group plc
MarketBeat –

Aberdeen Group plc purchased a new stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 301,848 shares of the…

marketbeat.com - NewAmsterdam Pharma Sees Unusually Large Options Volume (NASDAQ:NAMS)
NewAmsterdam Pharma Sees Unusually Large Options Volume (NASDAQ:NAMS)
MarketBeat –

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) saw some unusual options trading on Tuesday. Traders acquired 7,505 call options on the company. This is an increase of approximately 962% compared to the typical volume of 707 call…

marketbeat.com - NewAmsterdam Pharma Sees Unusually High Options Volume (NASDAQ:NAMS)
NewAmsterdam Pharma Sees Unusually High Options Volume (NASDAQ:NAMS)
MarketBeat –

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) was the target of some unusual options trading on Tuesday. Stock traders purchased 7,505 call options on the company. This is an increase of 962% compared to the typical volume of 707…

marketbeat.com - Avalyn Pharma (NASDAQ:AVLN) Stock Falls 8.1% Following Analyst Downgrade
Avalyn Pharma (NASDAQ:AVLN) Stock Falls 8.1% Following Analyst Downgrade
MarketBeat –

Avalyn Pharma Inc. (NASDAQ:AVLN - Get Free Report) traded down 8.1% on Tuesday after Morgan Stanley lowered their price target on the stock from $57.00 to $53.00. Morgan Stanley currently has an overweight rating on the stock. Avalyn Pharma traded…

marketbeat.com - Avalyn Pharma (NASDAQ:AVLN) Share Price Crosses Below Fifty Day Moving Average on Analyst Downgrade
Avalyn Pharma (NASDAQ:AVLN) Share Price Crosses Below Fifty Day Moving Average on Analyst Downgrade
MarketBeat –

Avalyn Pharma Inc. (NASDAQ:AVLN - Get Free Report) shares passed below its 50-day moving average during trading on Tuesday after Morgan Stanley lowered their price target on the stock from $57.00 to $53.00. The stock has a 50-day moving average of…

thehindubusinessline.com - KS Badri Narayanan - Stocks to watch, Nov 18: ArMee Info, IIFL Finance, RITES, Supreme Petrochem, Glenmark, Mankind Pharma, Ashok Buildcon, Advait Energy, Apollo Micro, Nykaa
Stocks to watch, Nov 18: ArMee Info, IIFL Finance, RITES, Supreme Petrochem, Glenmark, Mankind Pharma, Ashok Buildcon, Advait Energy, Apollo Micro, Nykaa
The HinduBusinessLine –

RITES has entered into an MoU with National Mission for Clean Ganga [an authority under the Environment (Protection) Act, 1986 (EPA)]. This MoU will establish a long term working mechanism between RITES and NMCG to collaborate on the preparation of…

seekingalpha.com - Albert Anthony - One Liberty Properties: Upgrade After Q3, As Industrial Portfolio Grows Selectively
One Liberty Properties: Upgrade After Q3, As Industrial Portfolio Grows Selectively
Seeking Alpha –

Albert Anthony is the pen name of a business author on Amazon and a contributing analyst to investing platforms like Seeking Alpha since 2023, where he has over + 2,000 followers and has covered hundreds of stocks in multiple sectors including…

techcrunch.com - Ram Iyer - Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials
Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials
TechCrunch –

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google's DeepMind in 2021, has raised $5 billion in a Series C funding round as it seeks to take its drug candidates to clinical trials. The funding was co-led by Greenoaks and…

afr.com - Joyce Moullakis - Nuix takeover offer caps off a wild six-year rollercoaster ride
Nuix takeover offer caps off a wild six-year rollercoaster ride
Australian Financial Review –

It's almost exactly six years since Nuix debuted on the ASX with much fanfare, and now it looks as though the analytics and intelligence software group will be plucked off the exchange in the coming months. The Macquarie-backed business is just the…

thehindubusinessline.com - Team BL - Stock Market Today Live: Stock to buy today: Cemindia Projects (₹1,353) - BUY
Stock Market Today Live: Stock to buy today: Cemindia Projects (₹1,353) - BUY
The HinduBusinessLine –

Indian stock markets are set to open weak amid mixed global cues, with Gift Nifty signaling a gap-down as consolidation dominates. Stocks to watch on Nov 18: ArMee, IIFL Finance, RITES, Supreme Petrochem, Glenmark, Mankind Pharma, Ashok Buildcon…

seekingalpha.com - Galzus Research - Immunome: De-Risked With The FDA, With An Admirably Deep Clinical Bench
Immunome: De-Risked With The FDA, With An Admirably Deep Clinical Bench
Seeking Alpha –

I maintain a Buy on Immunome, Inc.: its $2.1 billion market cap leaves upside versus the Springworks acquisition valuation. Varegacestat's phase 3 progression-free survival hazard ratio was 0.16; the FDA decision is due April 28, 2027, though…

econotimes.com - Celia Rowan - Economic Times Reports 16 Indian Microcaps More Than Doubled So Far in 2026
Economic Times Reports 16 Indian Microcaps More Than Doubled So Far in 2026
EconoTimes –

The Economic Times reported that 16 constituents of India's Nifty Microcap 250 more than doubled so far in 2026, while the index gained 13%, pointing to sharply uneven returns across the market. The outlet's Nov. 18 screen put Sigma Advanced…

siliconrepublic.com - Laura Varley - From a pharmacy job at 13 to leading a cell and gene therapy firm
From a pharmacy job at 13 to leading a cell and gene therapy firm
Silicon Republic –

Exmoor Pharma's Lucy Foley explores the cell and gene therapy landscape and scaling innovation. For Lucy Foley, the CEO of cell and gene therapy manufacturer Exmoor Pharma, there was no one moment that led her to a career in the medical sector…

Receive a Daily briefing on Pharma Industry News

Get Started